Gain Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Gain Therapeutics, Inc. | GANX - NASDAQ |
$10.00-$12.00 | $11.00 | $11.22 | 3.6 million | 3/18/2021 |
| BTIG, Oppenheimer | ||||||
Co-Manager(s): National Securities
| ||||||
| Health Care | ||||||
Filing(s): Filed 2021-02-19 Terms Added 2021-03-10 | ||||||
Gain Therapeutics, Inc. Quote & Chart - Click for current quote - GANX
IPO Boutique aggregates information on public companies and private companies, such as "GANX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Gain Therapeutics, Inc. (adapted from Gain Therapeutics, Inc. prospectus):
They are a development stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders, including rare genetic diseases and neurological disorders.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a development stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders, including rare genetic diseases and neurological disorders.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "GANX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.